Boosting systemic and secreted antibody responses in mice orally immunized with recombinantBacillus subtilisstrains following parenteral priming with a DNA vaccine encoding the enterotoxigenicEscherichia coli(ETEC) CFA/I fimbriae B subunit

RecombinantBacillus subtilisstrains, either spores or vegetative cells, may be employed as safe and low cost orally delivered live vaccine vehicles. In this study, we report the use of an orally deliveredB. subtilisvaccine strain to boost systemic and secreted antibody responses in mice i.m. primed...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2008-07, Vol.26 (32), p.3998
Main Authors: Luiz, Wilson B, Cavalcante, Rafael CM, Paccez, JulianoD, Souza, Renata D, Sbrogio-Almeida, Maria E, Ferreira, Rita CC, Ferreira, Luís CS
Format: Article
Language:English
Subjects:
Bacteriology
Deoxyribonucleic acid
DNA
Immunization
Medical research
Plasmids
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RecombinantBacillus subtilisstrains, either spores or vegetative cells, may be employed as safe and low cost orally delivered live vaccine vehicles. In this study, we report the use of an orally deliveredB. subtilisvaccine strain to boost systemic and secreted antibody responses in mice i.m. primed with a DNA vaccine encoding the structural subunit (CfaB) of the CFA/I fimbriae encoded by enterotoxigenicEscherichia coli(ETEC), an important etiological agent of diarrhea among travelers and children living in endemic regions. DBA/2 female mice submitted to the prime-boost immunization regimen developed synergic serum (IgG) and mucosal (IgA) antibody responses to the target CfaB antigen. Moreover, in contrast to mice immunized only with one vaccine formulation, sera harvested from prime-boosted vaccinated individuals inhibited adhesion of ETEC cells to human red blood cells. Additionally, vaccinated dams conferred full passive protection to suckling newborn mice challenged with a virulent ETEC strain. Taken together the present results further demonstrate the potential use of recombinantB. subtilisstrains as an alternative live vaccine vehicle.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.05.030